CanBas4575 
$5.66-7.90%24h
-7.90%24h
Global rank19741
Market cap$84.87M
Change 7d-2.64%
YTD Performance-7.52%
SP500 benchmarkUnderperform
P/E-0.07
P/S0
Revenue$0
Earnings-$7.95M
Dividend yield-
CanBas (4575) Stock Overview
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
4575 Stock Information
Symbol
4575Address
2-2-1, OtemachiNumazu, 410-0801Japan
Founded
-Trading hours
-Website
https://www.canbas.co.jpCountry
🇯🇵 JapanPhone Number
81 55 954 3666CanBas (4575) Price Chart
-
Value:-
CanBas Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $5.66 | N/A |
| Market Cap | $84.87M | N/A |
| Shares Outstanding | 14.98M | 54.67% |
| Employees | 12.00 | N/A |
| Shareholder Equity | 1.93B | 670.74% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | -0.07 | N/A |
| P/B Ratio | 0.04 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | -0.0041 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $0 | N/A |
| Earnings | -$7.95M | N/A |
| EPS | -83.03 | N/A |
| Earnings Yield | -14.66 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $13.34M | N/A |
| Cash on Hand | $10.34M | N/A |
| Debt to Equity | 0.0005 | -96.30% |
| Current Ratio | $13.44 | 205.92% |
